HELICOBACTER PYLORI INFECTIONS
42
10
11
11
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 42 trials
100.0%
+13.4% vs benchmark
29%
12 trials in Phase 3/4
0%
0 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 11 completed trials
Clinical Trials (42)
Efficacy and Safety of Second-Line Helicobacter Pylori Eradication
Lignin in Treatment of Helicobacter Pylori Infection
Feasibility and Performance of FFPE qPCR for Detection of Clarithromycin Resistance in Helicobacter Pylori
Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection
Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection
Efficacy and Safety of 14-Day Vonoprazan-Minocycline Dual Therapy for Helicobacter Pylori Eradication
Optimizing H. Pylori Eradication Regimen Under Intensified Acid Suppression
H. Pylori Infection and Metabolic Syndrome: A Retrospective Cross-Sectional Study
The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori
Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication
Levofloxacin-Based Sequential Therapy Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing
Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial
Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.
Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study
Registry for the Management of Helicobacter Pylori Infection in Shandong Province
Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy
Predicting Peptic Complications Using H. Pylori Serology and Gastric Ultrasound
Fecal Molecular Susceptibility-guided Hp First-line Therapy
Real-World Study of Helicobacter Pylori Eradication Success and Its Determinants